David Schwicker, MA, Economics and Business Administration
ORPHA Strategy Consulting
ORPHA Strategy Consulting, an independent consultancy based in Basle, Switzerland, is focussed on two specialties:
for orphan, specialty and advanced medicines. We provide insights and support to our clients for the development of early market access strategies, the feasibility and benefits of orphan designation,compassionate use programs, and evidence generation strategies for “fast to market” benefit/risk and value demonstration, including early global value dossiers (eGVD).
is increasingly crucial in rare diseases, where the collection of data via traditional routes is difficult. We propose pre-planning real-world research as an integral component of an early access “fast to market” strategy in a life-cycle approach. We support our clients in the strategic evidence generation planning and design of real-world and patient-centric research from very early in development to post-authorisation, with a focus on innovative, adaptive development pathways that emphasise the use of real-world evidence.
Marlene Haffner MD, MPH
Marlene serves as a Board Member on BioPharma Global and provides Technical Advice and Executive Oversight, and in addition she serves as a Key Regulatory Advisor on BioPharma Global client projects. Marlene continues to apply her extensive experience in development of orphan products by working with small to large biotech/pharmaceutical companies, patient advocacy groups, and government agencies. In addition Marlene serves as an expert advisor and board member to companies throughout the world. Trained as an internist and hematologist, Marlene graduated from the George Washington University School of Medicine and did further training at the Columbia University School of Medicine and the Albert Einstein College of Medicine, in New York City. She received her Masters of Public Health from the Johns Hopkins Bloomberg School of Public Health in Baltimore. Following her tenure at FDA and prior to forming Haffner Associates, Marlene served as Executive Director, Global Regulatory Intelligence and Policy for two years at Amgen, the largest biotech company in the world.
Marlene has worked in the Washington, DC metropolitan area for more than 30 years. She has seen many changes in the regulatory scene during that period of time and is both sensitive and knowledgeable about politics and the political landscape. She knows “FDA think” and maintains close ties with her friends and colleagues in the agency.